Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'NEUROLEPTICS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1321 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Giorgio D'Allio; fernando Rutto; Michela Coppi; Luca Guidi
      Livello di dipendenza dai Servizi Territoriali e costi relativi al trattamento della schizofrenia

      Farmeconomia e percorsi terapeutici
    2. Egidio Filippelli; Giovanni Biricolti; Cinzia Scarano; Federico Russo; Lucio Luciano
      Il trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici: una valutazione comparativa di costo/efficacia in una realtÓ psichiatrica locale

      Farmeconomia e percorsi terapeutici
    3. Angelomarco Barioglio; Luca Guidi; Giorgio Mariani
      Influenza del trattamento della schizofrenia con neurolettici tipici o olanzapina sui costi sanitari e sugli outcomes lavorativi

      Farmeconomia e percorsi terapeutici
    4. Felice Vadruccio; Giovanni Biricolti; Leonardo Mendolicchio
      Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale

      Farmeconomia e percorsi terapeutici
    5. Peuskens, J; De Hert, M; Jones, M
      The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    6. Melone, M; Vitellaro-Zuccarello, L; Vallejo-Illarramendi, A; Perez-Samartin, A; Matute, C; Cozzi, A; Pellegrini-Giampietro, DE; Rothstein, JD; Conti, F
      The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine

      MOLECULAR PSYCHIATRY
    7. Gimenez-Roldan, S; Mateo, D; Navarro, E; Gines, MM
      Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis

      PARKINSONISM & RELATED DISORDERS
    8. Hirose, S; Ashby, CR; Mills, MJ
      Effectiveness of ECT combined with risperidone against aggression in schizophrenia

      JOURNAL OF ECT
    9. Tang, WK; Ungvari, GS
      Rehab rounds - Electroconvulsive therapy in rehabilitation: The Hong Kong experience

      PSYCHIATRIC SERVICES
    10. Wilke, M; Kaufmann, C; Grabner, A; Putz, B; Wetter, TC; Auer, DP
      Gray matter-changes and correlates of disease severity in schizophrenia: Astatistical parametric mapping study

      NEUROIMAGE
    11. Sotnikova, TD; Gainetdinov, RR; Grekhova, TV; Rayevsky, KS
      Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study)

      PHARMACOLOGICAL RESEARCH
    12. Dose, M; Hahlweg, K
      Medicinal and psychological treatment of schizophrenia

      VERHALTENSTHERAPIE
    13. Hodgetts, KJ; Kieltyka, A; Brodbeck, R; Tran, JN; Wasley, JWF; Thurkauf, A
      6-(4-benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D-4 receptors

      BIOORGANIC & MEDICINAL CHEMISTRY
    14. Naidu, PS; Kulkarni, SK
      Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide

      BEHAVIOURAL PHARMACOLOGY
    15. Laviolette, SR; van der Kooy, D
      GABA(A) receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopaminergic neural motivationalsystems

      EUROPEAN JOURNAL OF NEUROSCIENCE
    16. Kaufmann, A; Ryser, B
      Multiresidue analysis of tranquilizers and the beta-blocker Carazolol in meat by liquid chromatography/tandem mass spectrometry

      RAPID COMMUNICATIONS IN MASS SPECTROMETRY
    17. Markianos, M; Hatzimanolis, J; Lykouras, L
      Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    18. Wiedemann, G; Hahlweg, K; Muller, U; Feinstein, E; Hank, G; Dose, M
      Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    19. Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M
      Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study

      PSYCHIATRY RESEARCH-NEUROIMAGING
    20. Kahkonen, S; Ahveninen, J; Pekkonen, E; Kaakkola, S; Huttunen, J; Peltonen, T; Ilmoniemi, RJ; Jaaskelainen, IP
      No evidence for dependence of early cortical auditory processing on dopamine D-2-receptor modulation: a whole-head magnetoencephalographic study

      PSYCHIATRY RESEARCH-NEUROIMAGING
    21. Schreinzer, D; Frey, R; Stimpfl, T; Vycudilik, W; Berzlanovich, A; Kasper, S
      Different fatal toxicity of neuroleptics identified by autopsy

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    22. Naber, D; Karow, A
      Good tolerability equals good results: the patient's perspective

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    23. Moritz, S; Andresen, B; Jacobsen, D; Mersmann, K; Wilke, U; Lambert, M; Naber, D; Krausz, M
      Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics

      EUROPEAN PSYCHIATRY
    24. Donohoe, G; Owens, N; O'Donnell, C; Burke, T; Moore, L; Tobin, A; O'Callaghan, E
      Predictors of compliance with neuroleptic medication among inpatients withschizophrenia: a discriminant function analysis

      EUROPEAN PSYCHIATRY
    25. Salzman, C
      Treatment of the agitation of late-life psychosis and Alzheimer's disease

      EUROPEAN PSYCHIATRY
    26. Altamura, AC; Bassetti, R; Sassella, F; Salvadori, D; Mundo, E
      Duration of untreated psychosis as a predictor of outcome in first-episodeschizophrenia: a retrospective study

      SCHIZOPHRENIA RESEARCH
    27. Hofer, E; Doby, D; Anderer, P; Dantendorfer, K
      Impaired conditional discrimination learning in schizophrenia

      SCHIZOPHRENIA RESEARCH
    28. Naber, D; Moritz, S; Lambert, M; Rajonk, F; Holzbach, R; Mass, R; Andresen, B; Frank, P; Rudiger, H; Reinhard, M; Burghard, A
      Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

      SCHIZOPHRENIA RESEARCH
    29. Quinn, J; Meagher, D; Murphy, P; Kinsella, A; Mullaney, J; Waddington, JL
      Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction

      SCHIZOPHRENIA RESEARCH
    30. Cuesta, MJ; Peralta, V; Zarzuela, A
      Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

      SCHIZOPHRENIA RESEARCH
    31. Purdon, SE; Labelle, A; Boulay, L
      Neuropsychological change in schizophrenia after 6 weeks of clozapine

      SCHIZOPHRENIA RESEARCH
    32. Maurer, I; Zierz, S; Moller, HJ
      Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia

      SCHIZOPHRENIA RESEARCH
    33. Mukherjee, J; Christian, BT; Narayanan, TK; Shi, BH; Mantil, J
      Evaluation of, dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using F-18-fallypride

      NEUROPSYCHOPHARMACOLOGY
    34. Benes, FM; Berretta, S
      GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder

      NEUROPSYCHOPHARMACOLOGY
    35. Meador-Woodruff, JH; Davis, KL; Haroutunian, V
      Abnormal kainate receptor expression in prefrontal cortex in schizophrenia

      NEUROPSYCHOPHARMACOLOGY
    36. Danielsen, EH; Smith, D; Hermansen, F; Gjedde, A; Cumming, P
      Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo

      SYNAPSE
    37. Wiener, PK; Kiosses, DN; Klimstra, S; Murphy, C; Alexopoulos, GS
      A short-term inpatient program for agitated demented nursing home residents

      INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
    38. Belsham, B
      Glutamate and its role in psychiatric illness

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    39. Anjum, R; Roy, A; Marston, G
      Antipsychotic induced priapism in a man with an intellectual disability

      IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE
    40. Joutsiniemi, SL; Gross, A; Appelberg, B
      Marked clozapine-induced slowing of EEG background over frontal, central, and parietal scalp areas in schizophrenic patients

      JOURNAL OF CLINICAL NEUROPHYSIOLOGY
    41. Gaebel, W
      Strategies of long-term medication in schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    42. Friedlander, R; Lazar, S; Klancnik, J
      Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    43. Wirz-Justice, A; Haug, HJ; Cajochen, C
      Disturbed circadian rest-activity cycles in schizophrenia patients: An effect of drugs?

      SCHIZOPHRENIA BULLETIN
    44. Muller, MJ; Szegedi, A; Wetzel, H; Benkert, O
      Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression

      SCHIZOPHRENIA BULLETIN
    45. Evans, SM; Walsh, SL; Levin, FR; Foltin, RW; Fischman, MW; Bigelow, GE
      Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans

      DRUG AND ALCOHOL DEPENDENCE
    46. Angrist, B; Sanfilipo, M; Wolkin, A
      Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol

      CLINICAL NEUROPHARMACOLOGY
    47. Svedberg, B; Lutzen, K
      Psychiatric nurses' attitudes towards patient autonomy in depot clinics

      JOURNAL OF ADVANCED NURSING
    48. Melkersson, KI; Hulting, AL; Rane, AJ
      Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    49. Bast, T; Zhang, WN; Heidbreder, C; Feldon, J
      Hyperactivity and disruption of prepulse inhibition induced by N-methyl-D-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine

      NEUROSCIENCE
    50. Wada, H; Nakajoh, K; Satoh-Nakagawa, T; Suzuki, T; Ohrui, T; Arai, H; Sasaki, H
      Risk factors of aspiration pneumonia in Alzheimer's disease patients

      GERONTOLOGY
    51. Green, B
      Focus on ziprasidone

      CURRENT MEDICAL RESEARCH AND OPINION
    52. Niizato, K; Genda, K; Nakamura, R; Iritani, S; Ikeda, K
      Cognitive decline in schizophrenics with Alzheimer's disease: A mini-review of neuropsychological and neuropathological studies

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    53. Kaneda, Y; Fujii, A; Nagamine, I
      Platelet serotonin concentrations in medicated schizophrenic patients

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    54. Ruggiero, GM; Laini, V; Mauri, MC; Ferrari, VMS; Clemente, A; Lugo, F; Mantero, M; Redaelli, G; Zappulli, D; Cavagnini, F
      A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    55. Ban, TA
      Pharmacotherapy of mental illness - A historical analysis

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    56. Lykouras, L; Markianos, M; Hatzimanolis, J; Oulis, P
      Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    57. Gjedde, A; Wong, DF
      Quantification of neuroreceptors in living human brain. V. Endogenous neurotransmitter inhibition of haloperidol binding in psychosis

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    58. Videbaek, C; Toska, K; Friberg, L; Holm, S; Angelo, HR; Knudsen, GM
      In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by[I-123]IBZM and single photon emission computed tomography

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    59. Xiberas, X; Martinot, JL; Mallet, L; Artiges, E; Canal, M; Loc'h, C; Maziere, B; Paillere-Martinot, ML
      In vitro extrastriatal and striatal D-2 dopamine receptor blockade by amisulpride in schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    60. Chong, SA; Remington, G; Mahendran, R; Chua, HC
      Awareness of tardive dyskinesia in Asian patients with schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    61. Lahdelma, L; Ahokas, A; Andersson, LC; Suvisaari, J; Hovatta, I; Huttunen, MO; Koskimies, S
      Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    62. Procyshyn, RM; Ihsan, N; Thompson, D
      A comparison of smoking behaviours between patients treated with clozapineand depot neuroleptics

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    63. Kasper, S; Rosillon, D; Duchesne, I
      Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    64. Kasper, S; Jones, M; Duchesne, I
      Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    65. Fakhoury, WKH; Wright, D; Wallace, M
      Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    66. Licht, RW; Bysted, M; Christensen, H
      Fixed-dosed risperidone in mania: an open experimental trial

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    67. Fanello, S; Blay, M; Laine-Cessac, P; Daryabin, M
      Hypothermia induced by neuroleptics

      REVUE DE MEDECINE INTERNE
    68. Braus, DF; Ende, G; Weber-Fahr, W; Demirakca, T; Henn, FA
      Favorable effect on neuronal viability in the anterior cingulate gyrus dueto long-term treatment with atypical antipsychotics: An MRSI study

      PHARMACOPSYCHIATRY
    69. Schmidt, K; Nolte-Zenker, B; Patzer, J; Bauer, M; Schmidt, LG; Heinz, A
      Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence

      PHARMACOPSYCHIATRY
    70. Sawaguchi, T
      The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task

      NEUROSCIENCE RESEARCH
    71. Manzanedo, C; Aguilar, MA; Rodriguez-Arias, M; Minarro, J
      Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice

      BEHAVIOURAL BRAIN RESEARCH
    72. Brown, ES; Suppes, T; Adinoff, B; Thomas, NR
      Drug abuse and bipolar disorder: comorbidity or misdiagnosis?

      JOURNAL OF AFFECTIVE DISORDERS
    73. Sweet, RA; Henteleff, RA; Meinert, KA; DeMichele, MAA; Kirshner, MA; Sorisio, DA; Pollock, BG
      Antipsychotic radioreceptor assay: A modification identifying selective receptor effects

      THERAPEUTIC DRUG MONITORING
    74. Angelo, HR; Petersen, A
      Therapeutic drug monitoring of haloperidol, perphenazine, and zuclopenthixol in serum by a fully automated sequential solid phase extraction followedby high-performance liquid chromatography

      THERAPEUTIC DRUG MONITORING
    75. Bickeboeller-Friedrich, J; Maurer, HH
      Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes

      THERAPEUTIC DRUG MONITORING
    76. Simpson, MM; Goetz, RR; Devlin, MJ; Goetz, SA; Walsh, BT
      Weight gain and antipsychotic medication: Differences between antipsychotic-free and treatment periods

      JOURNAL OF CLINICAL PSYCHIATRY
    77. Silver, AA; Shytle, RD; Philipp, MK; Wilkinson, BJ; McConville, B; Sanberg, PR
      Transdermal nicotine and haloperidol in Tourette's disorder: A double-blind placebo-controlled study

      JOURNAL OF CLINICAL PSYCHIATRY
    78. Malla, AK; Norman, RMG; Scholten, DJ; Zirul, S; Kotteda, V
      A comparison of long-term outcome in first-episode schizophrenia followingtreatment with risperidone or a typical antipsychotic

      JOURNAL OF CLINICAL PSYCHIATRY
    79. Kurzthaler, I; Fleischhacker, WW
      The clinical implications of weight gain in schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    80. Zhang, KH; Tarazi, FI; Baldessarini, RJ
      Nigrostriatal dopaminergic denervation enhances dopamine D-4 receptor binding in rat caudate-putamen

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    81. Siegel, DM; Grudzinskas, AJ; Pinals, DA
      Old law meets new medicine: Revisiting involuntary psychotropic medicationof the criminal defendant

      WISCONSIN LAW REVIEW
    82. Rodriguez-Ferrera, S; McCarthy, RA; McKenna, PJ
      Language in schizophrenia and its relationship to formal thought disorder

      PSYCHOLOGICAL MEDICINE
    83. Sernyak, MJ; Kosten, TR; Fontana, A; Rosenheck, R
      Neuroleptic use in the treatment of Post-Traumatic Stress Disorder

      PSYCHIATRIC QUARTERLY
    84. Ruths, S; Straand, J; Nygaard, HA
      Psychotropic drug use in nursing homes - diagnostic indications and variations between institutions

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    85. Steinert, T; Hinuber, W; Arenz, D; Rottgers, HR; Biller, N; Gebhardt, RP
      Ethical conflicts in involuntary treatment of patients with schizophrenia.Decision-making and control of variables in three case reports

      NERVENARZT
    86. Gil, FP; Schneider, C; Grohmann, R; Ruther, E
      Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy

      NERVENARZT
    87. Grunder, G; Vernaleken, I; Benkert, O
      Which properties make a neuroleptic "atypical"?

      NERVENARZT
    88. Garolera, D; Bendahan, G; Gras, R; Benaque, A; San Jose, A; Vilardell, M
      Psychoactive drug use in nursing homes

      MEDICINA CLINICA
    89. Viyoch, J; Ohdo, S; Yukawa, E; Higuchi, S
      Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    90. Tarazi, FI; Zhang, K; Baldessarini, RJ
      Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    91. Warawa, EJ; Migler, BM; Ohnmacht, CJ; Needles, AL; Gatos, GC; McLaren, FM; Nelson, CL; Kirkland, KM
      Behavioral approach to nondyskinetic dopamine antagonists: Identification of seroquel

      JOURNAL OF MEDICINAL CHEMISTRY
    92. Inoue, A; Nakata, Y
      Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy

      JAPANESE JOURNAL OF PHARMACOLOGY
    93. Kawashima, N; Funakoshi, T; Omura, T; Chaki, S; Kameo, K; Okuyama, S
      Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    94. Hertel, P; Byskov, L; Didriksen, M; Arnt, J
      Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity

      EUROPEAN JOURNAL OF PHARMACOLOGY
    95. Curran, MP; Perry, CM
      Amisulpride - A review of its use in the management of schizophrenia

      DRUGS
    96. Jutila, A; Soderlund, T; Pakkanen, AL; Huttunen, M; Kinnunen, PKJ
      Comparison of the effects of clozapine, chlorpromazine and haloperidol on membrane lateral heterogeneity

      CHEMISTRY AND PHYSICS OF LIPIDS
    97. Adams, CE; Fenton, MKP; Quraishi, S; David, AS
      Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

      BRITISH JOURNAL OF PSYCHIATRY
    98. Walburn, J; Gray, R; Gournay, K; Quraishi, S; David, AS
      Systematic review of patient and nurse attitudes to depot antipsychotic medication

      BRITISH JOURNAL OF PSYCHIATRY
    99. Daniel, WA; Wojcikowski, J; Palucha, A
      Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping

      BRITISH JOURNAL OF PHARMACOLOGY
    100. Nopoulos, PC; Ceilley, JW; Gailis, EA; Andreasen, NC
      An MRI study of midbrain morphology in patients with schizophrenia: Relationship to psychosis, neuroleptics, and cerebellar neural circuitry

      BIOLOGICAL PSYCHIATRY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 09:45:34